Vancomycin-resistente enterokokken: Welche therapieoptionen gibt es?

Nico T. Mutters; Guido Werner; Evelina Tacconelli; Alexander Mischnik

doi:10.1055/s-0040-100428

Vancomycin-resistente enterokokken: Welche therapieoptionen gibt es?

Translated title of the contribution: Treatment options for serious infections caused by vancomycin-resistant enterococci

Nico T. Mutters, Guido Werner, Evelina Tacconelli, Alexander Mischnik^*

^*Corresponding author for this work

Institute of Medical Microbiology

6 Citations (Scopus)

Abstract

Abstract Complicated infections caused by vancomycin-resistant enterococci (VRE) represent a therapeutic challenge, since adequate treatment options are limited and antibiotic resistance to the available agents has already been described. The most frequently used antibiotic in VRE treatment is linezolid. Tigecycline is an alternative to linezolid, however, clinical data for severe infections such as sepsis or endocarditis are scarce. Daptomycin on the one hand is an option but has not yet been approved for the treatment of enterococcal infections in Germany on the other hand. The present review critically evaluates the clinical significance of the antibiotics in question for VRE therapy based on existing data.

Translated title of the contribution	Treatment options for serious infections caused by vancomycin-resistant enterococci
Original language	German
Journal	Deutsche Medizinische Wochenschrift
Volume	140
Issue number	1
Pages (from-to)	42-45
Number of pages	4
ISSN	0012-0472
DOIs	https://doi.org/10.1055/s-0040-100428
Publication status	Published - 12.01.2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research Areas and Centers

Academic Focus: Center for Infection and Inflammation Research (ZIEL)

Access to Document

10.1055/s-0040-100428

Cite this

@article{7cb7207e61dd467fbe0e16599333fc6a,

title = "Vancomycin-resistente enterokokken: Welche therapieoptionen gibt es?",

abstract = "Abstract Complicated infections caused by vancomycin-resistant enterococci (VRE) represent a therapeutic challenge, since adequate treatment options are limited and antibiotic resistance to the available agents has already been described. The most frequently used antibiotic in VRE treatment is linezolid. Tigecycline is an alternative to linezolid, however, clinical data for severe infections such as sepsis or endocarditis are scarce. Daptomycin on the one hand is an option but has not yet been approved for the treatment of enterococcal infections in Germany on the other hand. The present review critically evaluates the clinical significance of the antibiotics in question for VRE therapy based on existing data.",

author = "Mutters, \{Nico T.\} and Guido Werner and Evelina Tacconelli and Alexander Mischnik",

year = "2015",

month = jan,

day = "12",

doi = "10.1055/s-0040-100428",

language = "Deutsch",

volume = "140",

pages = "42--45",

journal = "Deutsche Medizinische Wochenschrift",

issn = "0012-0472",

publisher = "Georg Thieme Verlag",

number = "1",

}

TY - JOUR

T1 - Vancomycin-resistente enterokokken

T2 - Welche therapieoptionen gibt es?

AU - Mutters, Nico T.

AU - Werner, Guido

AU - Tacconelli, Evelina

AU - Mischnik, Alexander

PY - 2015/1/12

Y1 - 2015/1/12

N2 - Abstract Complicated infections caused by vancomycin-resistant enterococci (VRE) represent a therapeutic challenge, since adequate treatment options are limited and antibiotic resistance to the available agents has already been described. The most frequently used antibiotic in VRE treatment is linezolid. Tigecycline is an alternative to linezolid, however, clinical data for severe infections such as sepsis or endocarditis are scarce. Daptomycin on the one hand is an option but has not yet been approved for the treatment of enterococcal infections in Germany on the other hand. The present review critically evaluates the clinical significance of the antibiotics in question for VRE therapy based on existing data.

AB - Abstract Complicated infections caused by vancomycin-resistant enterococci (VRE) represent a therapeutic challenge, since adequate treatment options are limited and antibiotic resistance to the available agents has already been described. The most frequently used antibiotic in VRE treatment is linezolid. Tigecycline is an alternative to linezolid, however, clinical data for severe infections such as sepsis or endocarditis are scarce. Daptomycin on the one hand is an option but has not yet been approved for the treatment of enterococcal infections in Germany on the other hand. The present review critically evaluates the clinical significance of the antibiotics in question for VRE therapy based on existing data.

UR - https://www.scopus.com/pages/publications/84925282756

U2 - 10.1055/s-0040-100428

DO - 10.1055/s-0040-100428

M3 - Zeitschriftenaufsätze

C2 - 25580973

AN - SCOPUS:84925282756

SN - 0012-0472

VL - 140

SP - 42

EP - 45

JO - Deutsche Medizinische Wochenschrift

JF - Deutsche Medizinische Wochenschrift

IS - 1

ER -

Vancomycin-resistente enterokokken: Welche therapieoptionen gibt es?

Abstract

UN SDGs

Research Areas and Centers

Access to Document

Other files and links

Fingerprint

Cite this